1887

Abstract

which colonizes the gut mucosa via formation of attaching and effacing (A/E) lesions, causes transmissible colonic hyperplasia. The aim of this study was to evaluate whether prophylactic treatment with UCC2003 can improve the outcome of infection. Six-week-old albino C57BL/6 mice were pre-treated for 3 days with , challenged with bioluminescent and administered or PBS-C for 8 days post-infection; control mice were either administered and mock-infected with PBS, or mock-treated with PBS-C and mock-infected with PBS. colonization was monitored by bacterial enumeration from faeces and by a combination of both 2D bioluminescence imaging (BLI) and composite 3D diffuse light imaging tomography with µCT imaging (DLIT-µCT). At day 8 post-infection, colons were removed and assessed for crypt hyperplasia, histology by light microscopy, bacterial colonization by immunofluorescence, and A/E lesion formation by electron microscopy. Prophylactic administration of did not prevent colonization or A/E lesion formation. However, this treatment did alter distribution within the large intestine and significantly reduced colonic crypt hyperplasia at the peak of bacterial infection. These results show that could not competitively exclude , but reduced pathogen-induced colonic inflammation.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.060830-0
2012-11-01
2019-12-06
Loading full text...

Full text loading...

/deliver/fulltext/micro/158/11/2826.html?itemId=/content/journal/micro/10.1099/mic.0.060830-0&mimeType=html&fmt=ahah

References

  1. Bernet-Camard M. F., Liévin V., Brassart D., Neeser J. R., Servin A. L., Hudault S.. ( 1997;). The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. . Appl Environ Microbiol 63:, 2747–2753.[PubMed]
    [Google Scholar]
  2. Chen C. C., Louie S., Shi H. N., Walker W. A.. ( 2005;). Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis. . Pediatr Res 58:, 1185–1191. [CrossRef][PubMed]
    [Google Scholar]
  3. Chen X., Xu J., Shuai J., Chen J., Zhang Z., Fang W.. ( 2007;). The S-layer proteins of Lactobacillus crispatus strain ZJ001 is responsible for competitive exclusion against Escherichia coli O157 : H7 and Salmonella typhimurium. . Int J Food Microbiol 115:, 307–312. [CrossRef][PubMed]
    [Google Scholar]
  4. Chen C. C., Chiu C. H., Lin T. Y., Shi H. N., Walker W. A.. ( 2009;). Effect of probiotics Lactobacillus acidophilus on Citrobacter rodentium colitis: the role of dendritic cells. . Pediatr Res 65:, 169–175. [CrossRef][PubMed]
    [Google Scholar]
  5. Contag C. H., Contag P. R., Mullins J. I., Spilman S. D., Stevenson D. K., Benaron D. A.. ( 1995;). Photonic detection of bacterial pathogens in living hosts. . Mol Microbiol 18:, 593–603. [CrossRef][PubMed]
    [Google Scholar]
  6. Corr S. C., Li Y., Riedel C. U., O’Toole P. W., Hill C., Gahan C. G.. ( 2007;). Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. . Proc Natl Acad Sci U S A 104:, 7617–7621. [CrossRef][PubMed]
    [Google Scholar]
  7. Crepin V. F., Girard F., Schüller S., Phillips A. D., Mousnier A., Frankel G.. ( 2010;). Dissecting the role of the Tir : Nck and Tir : IRTKS/IRSp53 signalling pathways in vivo. . Mol Microbiol 75:, 308–323. [CrossRef][PubMed]
    [Google Scholar]
  8. Cronin M., Morrissey D., Rajendran S., El Mashad S. M., van Sinderen D., O’Sullivan G. C., Tangney M.. ( 2010;). Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. . Mol Ther 18:, 1397–1407. [CrossRef][PubMed]
    [Google Scholar]
  9. Cronin M., Akin A. R., Collins S. A., Meganck J., Kim J. B., Baban C. K., Joyce S. A., van Dam G. M., Zhang N.. & other authors ( 2012;). High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. . PLoS ONE 7:, e30940. [CrossRef][PubMed]
    [Google Scholar]
  10. D’Arienzo R., Maurano F., Mazzarella G., Luongo D., Stefanile R., Ricca E., Rossi M.. ( 2006;). Bacillus subtilis spores reduce susceptibility to Citrobacter rodentium-mediated enteropathy in a mouse model. . Res Microbiol 157:, 891–897. [CrossRef][PubMed]
    [Google Scholar]
  11. Doyle T. C., Burns S. M., Contag C. H.. ( 2004;). In vivo bioluminescence imaging for integrated studies of infection. . Cell Microbiol 6:, 303–317. [CrossRef][PubMed]
    [Google Scholar]
  12. Dundas S., Todd W. T., Neill M. A., Tarr P. I.. ( 2005;). Using antibiotics in suspected haemolytic-uraemic syndrome: antibiotics should not be used in Escherichia coli O157 : H7 infection. . BMJ 330:, 1209–, author reply 1209. [CrossRef][PubMed]
    [Google Scholar]
  13. Fanning S., Hall L. J., Cronin M., Zomer A., MacSharry J., Goulding D., O’Connell Motherway M., Shanahan F., Nally K.. & other authors ( 2012;). Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. . Proc Natl Acad Sci U S A 109:, 2108–2113. [CrossRef][PubMed]
    [Google Scholar]
  14. Felis G. E., Dellaglio F.. ( 2007;). Taxonomy of Lactobacilli and Bifidobacteria. . Curr Issues Intest Microbiol 8:, 44–61.[PubMed]
    [Google Scholar]
  15. FAO. ( 2001;). Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic acid Bacteria. http://www.who.int/foodsafety/publications/fs_management/probiotics/en/index.html.
  16. Fuller R.. ( 1992;). Probiotics: the Scientific Basis. Chapman & Hall;.
    [Google Scholar]
  17. Gareau M. G., Wine E., Reardon C., Sherman P. M.. ( 2010;). Probiotics prevent death caused by Citrobacter rodentium infection in neonatal mice. . J Infect Dis 201:, 81–91. [CrossRef][PubMed]
    [Google Scholar]
  18. Girard F., Dziva F., van Diemen P., Phillips A. D., Stevens M. P., Frankel G.. ( 2007;). Adherence of enterohemorrhagic Escherichia coli O157, O26, and O111 strains to bovine intestinal explants ex vivo. . Appl Environ Microbiol 73:, 3084–3090. [CrossRef][PubMed]
    [Google Scholar]
  19. Hardy J., Francis K. P., DeBoer M., Chu P., Gibbs K., Contag C. H.. ( 2004;). Extracellular replication of Listeria monocytogenes in the murine gall bladder. . Science 303:, 851–853. [CrossRef][PubMed]
    [Google Scholar]
  20. Health Protection Agency ( 2011;). E. coli O157 Annual Totals. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1249113624846.
    [Google Scholar]
  21. Huebner E. S., Surawicz C. M.. ( 2006;). Probiotics in the prevention and treatment of gastrointestinal infections. . Gastroenterol Clin North Am 35:, 355–365. [CrossRef][PubMed]
    [Google Scholar]
  22. Johnson-Henry K. C., Nadjafi M., Avitzur Y., Mitchell D. J., Ngan B. Y., Galindo-Mata E., Jones N. L., Sherman P. M.. ( 2005;). Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. . J Infect Dis 191:, 2106–2117. [CrossRef][PubMed]
    [Google Scholar]
  23. Jones S. E., Knight K. L.. ( 2012;). Bacillus subtilis-mediated protection from Citrobacter rodentium-associated enteric disease requires espH and functional flagella. . Infect Immun 80:, 710–719. [CrossRef][PubMed]
    [Google Scholar]
  24. Kuo C., Coquoz O., Troy T. L., Xu H., Rice B. W.. ( 2007;). Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. . J Biomed Opt 12:, 024007. [CrossRef][PubMed]
    [Google Scholar]
  25. McGannon C. M., Fuller C. A., Weiss A. A.. ( 2010;). Different classes of antibiotics differentially influence Shiga toxin production. . Antimicrob Agents Chemother 54:, 3790–3798. [CrossRef][PubMed]
    [Google Scholar]
  26. Medellin-Peña M. J., Wang H., Johnson R., Anand S., Griffiths M. W.. ( 2007;). Probiotics affect virulence-related gene expression in Escherichia coli O157 : H7. . Appl Environ Microbiol 73:, 4259–4267. [CrossRef][PubMed]
    [Google Scholar]
  27. Mundy R., MacDonald T. T., Dougan G., Frankel G., Wiles S.. ( 2005;). Citrobacter rodentium of mice and man. . Cell Microbiol 7:, 1697–1706. [CrossRef][PubMed]
    [Google Scholar]
  28. Panos G. Z., Betsi G. I., Falagas M. E.. ( 2006;). Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157 : H7 infection?. Aliment Pharmacol Ther 24:, 731–742. [CrossRef][PubMed]
    [Google Scholar]
  29. Picard C., Fioramonti J., Francois A., Robinson T., Neant F., Matuchansky C.. ( 2005;). Review article: bifidobacteria as probiotic agents – physiological effects and clinical benefits. . Aliment Pharmacol Ther 22:, 495–512. [CrossRef][PubMed]
    [Google Scholar]
  30. Preidis G. A., Hill C., Guerrant R. L., Ramakrishna B. S., Tannock G. W., Versalovic J.. ( 2011;). Probiotics, enteric and diarrheal diseases, and global health. . Gastroenterology 140:, 8–14. [CrossRef][PubMed]
    [Google Scholar]
  31. Rodrigues D. M., Sousa A. J., Johnson-Henry K. C., Sherman P. M., Gareau M. G.. ( 2012;). Probiotics are effective for the prevention and treatment of Citrobacter rodentium-induced colitis in mice. . J Infect Dis 206:, 99–109. [CrossRef][PubMed]
    [Google Scholar]
  32. Servin A. L.. ( 2004;). Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. . FEMS Microbiol Rev 28:, 405–440. [CrossRef][PubMed]
    [Google Scholar]
  33. Servin A. L., Coconnier M. H.. ( 2003;). Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. . Best Pract Res Clin Gastroenterol 17:, 741–754. [CrossRef][PubMed]
    [Google Scholar]
  34. Szittner R., Meighen E.. ( 1990;). Nucleotide sequence, expression, and properties of luciferase coded by lux genes from a terrestrial bacterium. . J Biol Chem 265:, 16581–16587.[PubMed]
    [Google Scholar]
  35. Tarr P. I., Gordon C. A., Chandler W. L.. ( 2005;). Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. . Lancet 365:, 1073–1086.[PubMed]
    [Google Scholar]
  36. Wiles S., Clare S., Harker J., Huett A., Young D., Dougan G., Frankel G.. ( 2004;). Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium. . Cell Microbiol 6:, 963–972. [CrossRef][PubMed]
    [Google Scholar]
  37. Wiles S., Dougan G., Frankel G.. ( 2005;). Emergence of a ‘hyperinfectious’ bacterial state after passage of Citrobacter rodentium through the host gastrointestinal tract. . Cell Microbiol 7:, 1163–1172. [CrossRef][PubMed]
    [Google Scholar]
  38. Wu X., Vallance B. A., Boyer L., Bergstrom K. S., Walker J., Madsen K., O’Kusky J. R., Buchan A. M., Jacobson K.. ( 2008;). Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. . Am J Physiol Gastrointest Liver Physiol 294:, G295–G306. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.060830-0
Loading
/content/journal/micro/10.1099/mic.0.060830-0
Loading

Data & Media loading...

Supplements

Supplementary movie 1. PBS-C+CR infection 

Supplementary movie 2. BB+CR infection 

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error